Zobrazeno 1 - 2
of 2
pro vyhledávání: '"John Schreurs"'
Autor:
Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A Dobber, Clemens Mellink, Anne-Marie F van der Kevie-Kersemaekers, Ludo M Evers, Fransien de Boer, Harry R Koene, John Schreurs, Marjolein van der Klift, Gerjo A Velders, Ellen van der Spek, Hanneke M van der Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F M Posthuma, Hein P J Visser, Ilse Houtenbos, Cecile A M Idink, Djamila E Issa, Ellen C Dompeling, Henk C T van Zaanen, Hendrik Veelken, Henriette Levenga, Lidwine W Tick, Wim E Terpstra, Sanne H Tonino, Michelle Boyer, Mehrdad Mobasher, Mark-David Levin, Arnon P Kater
Publikováno v:
The Lancet Haematology, 9(3), e190-e199. Lancet Publishing Group
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
Background Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0986e715312f80218fa9f8521d8b97ab
https://doi.org/10.1016/s2352-3026(22)00034-5
https://doi.org/10.1016/s2352-3026(22)00034-5
Autor:
Mels Hoogendoorn, Ellen van der Spek, Clemens Mellink, Fransien Croon-de Boer, Julie Dubois, Shulamiet Wittebol, Mehrdad Mobasher, Sanne H. Tonino, Arnon P. Kater, Mark-David Levin, John Schreurs, Cecile Idink, Hein Visser, Yvette van Norden, Sabina Kersting, L. M. Evers, Johan A. Dobber
Publikováno v:
Blood advances, 2(24), 3566-3571. American Society of Hematology
Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS). Whether optimal duration of venetocla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cfc81aa3a7833eaaf846c029226045c
https://doi.org/10.1182/bloodadvances.2018019422
https://doi.org/10.1182/bloodadvances.2018019422